Pharmaceuticals

Redhill Biopharma

RedHill Biopharma Announces Positive Preclinical Results for Opaganib in Combination with Venetoclax for Chronic Lymphocytic Leukemia

Cumberland Pharmaceuticals Makes Strategic Investment in RedHill Biopharma

RedHill Biopharma Signs License Agreement for Talicia with Middle East Market

Redhill Biopharma released FY2025 Semi-Annual Earnings on September 5, 2025 (EST) with actual revenue of USD 4.079 M and EPS of USD -2.2922

Redhill Biopharma released FY2025 Q1 earnings on September 5 (EST), actual revenue USD 2.04 M, actual EPS USD -1.1461

Redhill Biopharma released FY2025 Q2 earnings on September 5 (EST), actual revenue USD 2.04 M, actual EPS USD -1.1461

RedHill Biopharma Launches Phase II Clinical Trial for New Prostate Cancer Treatment

RedHill Biopharma signs stock purchase agreement with Alumni Capital

RedHill Supports H. pylori CME Program

RHB-107 Molecular Structure Receives Patent Protection

RedHill Biopharma Receives NASDAQ Non-Compliance Notice

RedHill's Opaganib Shows Progress in Obesity and Diabetes Management

Redhill Biopharma released FY2024 Q4 earnings on April 10 (EST), actual revenue USD 2.736 M, actual EPS USD -2.01

Redhill Biopharma released FY2024 Q3 earnings on April 10 (EST), with actual revenue of USD 2.736 M and EPS of USD -2.01

Redhill Biopharma released FY2024 annual earnings on April 10 (EST), actual revenue USD 8.043 M (forecast USD 20.8 M), actual EPS USD -6.7095 (forecast USD -40)

Redhill Biopharma released FY2024 9 Months Earnings on April 10 (EST), with actual revenue of USD 5.308 M and EPS of USD -4.6358

RedHill Biopharma Ltd. Releases Fiscal Year 2024 Financial Results with 23% Revenue Growth

RedHill Biopharma Reports 123% Increase in Net Income to $8 Million for FY 2024

Redhill Biopharma Submits Market Authorization Application for TALICIA® in the UK

Redhill Biopharma Advances RHB-104 Late-Stage Crohn's Disease Project

PicoCELA

Santech

Highway

Trinity Biotech

Euda Health

Aimei Health Tech

Sable Offshore

Pomdoctor

Ascent Solar Tech

A SPAC III Acquisition

礼来

罗氏(ADR)

ROCHE HOLDINGS AG

阿斯利康

诺华制药

诺和诺德公司

中外制药(ADR)

UCB(ADR)

第一三共株式会社(ADR)

大冢制药(ADR)

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap